Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 23677068)

1.

Molecular pathogenesis of malignant mesothelioma.

Sekido Y.

Carcinogenesis. 2013 Jul;34(7):1413-9. doi: 10.1093/carcin/bgt166. Epub 2013 May 14. Review.

2.

Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.

Sekido Y.

Pathol Int. 2011 Jun;61(6):331-44. doi: 10.1111/j.1440-1827.2011.02666.x. Epub 2011 May 2. Review.

PMID:
21615608
3.

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.

Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI.

Cancer Res. 2015 Jan 15;75(2):264-9. doi: 10.1158/0008-5472.CAN-14-1008. Epub 2014 Dec 8.

PMID:
25488749
4.

BAP1 protein is a progression factor in malignant pleural mesothelioma.

Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH.

Pathol Oncol Res. 2014 Jan;20(1):145-51. doi: 10.1007/s12253-013-9677-2. Epub 2013 Aug 22.

PMID:
23963927
5.

Germline BAP1 mutations predispose to malignant mesothelioma.

Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M.

Nat Genet. 2011 Aug 28;43(10):1022-5. doi: 10.1038/ng.912.

6.

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M, Giancotti F.

Clin Cancer Res. 2012 Sep 1;18(17):4485-90. doi: 10.1158/1078-0432.CCR-11-2375. Epub 2012 Jul 23.

7.

LATS2 is a tumor suppressor gene of malignant mesothelioma.

Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, Toyokuni S, Osada H, Sekido Y.

Cancer Res. 2011 Feb 1;71(3):873-83. doi: 10.1158/0008-5472.CAN-10-2164. Epub 2011 Jan 18.

8.

Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.

Carbone M, Yang H.

Clin Cancer Res. 2012 Feb 1;18(3):598-604. doi: 10.1158/1078-0432.CCR-11-2259. Epub 2011 Nov 7.

9.

Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.

Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H, Karar J, Rauscher FJ, Testa JR.

Cancer Res. 2014 Aug 15;74(16):4388-97. doi: 10.1158/0008-5472.CAN-14-1328. Epub 2014 Jun 13.

PMID:
24928783
10.

Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.

Menges CW, Kadariya Y, Altomare D, Talarchek J, Neumann-Domer E, Wu Y, Xiao GH, Shapiro IM, Kolev VN, Pachter JA, Klein-Szanto AJ, Testa JR.

Cancer Res. 2014 Feb 15;74(4):1261-71. doi: 10.1158/0008-5472.CAN-13-2062. Epub 2013 Dec 26.

11.

Pathological and molecular biological approaches to early mesothelioma.

Tsujimura T, Torii I, Sato A, Song M, Fukuoka K, Hasegawa S, Nakano T.

Int J Clin Oncol. 2012 Feb;17(1):40-7. doi: 10.1007/s10147-011-0369-1. Epub 2012 Jan 12. Review.

PMID:
22237727
12.

Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells.

Sekido Y.

Cancer Sci. 2010 Jan;101(1):1-6. doi: 10.1111/j.1349-7006.2009.01336.x. Epub 2009 Sep 1. Review.

PMID:
19793348
13.

Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma.

Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L, Fleury-Feith J, Zucman-Rossi J, Giovannini M, Jaurand MC.

Cell Cycle. 2005 Dec;4(12):1862-9. Epub 2005 Dec 7.

14.

Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.

Andujar P, Lecomte C, Renier A, Fleury-Feith J, Kheuang L, Daubriac J, Janin A, Jaurand MC.

Carcinogenesis. 2007 Jul;28(7):1599-605. Epub 2007 Feb 1.

15.

CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis.

Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S.

Genes Chromosomes Cancer. 2009 Jul;48(7):615-23. doi: 10.1002/gcc.20669.

PMID:
19396864
16.

Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma.

Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S, Okumura Y, Tanaka F, Hasegawa S, Nakano T, Hashimoto-Tamaoki T.

Cancer Sci. 2012 May;103(5):868-74. doi: 10.1111/j.1349-7006.2012.02223.x. Epub 2012 Feb 21.

PMID:
22321046
17.

Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma.

Murthy SS, Testa JR.

J Cell Physiol. 1999 Aug;180(2):150-7. Review.

PMID:
10395284
18.

Molecular biology of malignant mesothelioma.

Sekido Y.

Environ Health Prev Med. 2008 Mar;13(2):65-70. doi: 10.1007/s12199-007-0015-8. Epub 2008 Feb 28.

19.

A mouse model recapitulating molecular features of human mesothelioma.

Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR.

Cancer Res. 2005 Sep 15;65(18):8090-5.

20.

Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.

Ribeiro C, Campelos S, Moura CS, Machado JC, Justino A, Parente B.

Ann Oncol. 2013 Aug;24(8):2147-50. doi: 10.1093/annonc/mdt135. Epub 2013 Apr 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk